Polina Sysa-Shah
Overview
Explore the profile of Polina Sysa-Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Minn I, Huss D, Ahn H, Chinn T, Park A, Jones J, et al.
Sci Adv
. 2019 Jul;
5(7):eaaw5096.
PMID: 31281894
Chimeric antigen receptor (CAR) T cell therapy for hematologic malignancies is fraught with several unknowns, including number of functional T cells that engage target tumor, durability and subsequent expansion and...
12.
Gabrielson K, Maronpot R, Monette S, Mlynarczyk C, Ramot Y, Nyska A, et al.
ILAR J
. 2018 Dec;
59(1):80-98.
PMID: 30541081
Preclinical noninvasive imaging can be an indispensable tool for studying animal models of disease. In vivo imaging to assess anatomical, functional, and molecular features requires verification by a comparison to...
13.
Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, et al.
J Clin Invest
. 2018 Nov;
129(2):616-630.
PMID: 30457978
Immune checkpoint therapies have shown tremendous promise in cancer therapy. However, tools to assess their target engagement, and hence the ability to predict their efficacy, have been lacking. Here, we...
14.
Gomez J, Bonaventura J, Lesniak W, Mathews W, Sysa-Shah P, Rodriguez L, et al.
Science
. 2017 Aug;
357(6350):503-507.
PMID: 28774929
The chemogenetic technology DREADD (designer receptors exclusively activated by designer drugs) is widely used for remote manipulation of neuronal activity in freely moving animals. DREADD technology posits the use of...
15.
Maronpot R, Nyska A, Troth S, Gabrielson K, Sysa-Shah P, Kalchenko V, et al.
Toxicol Pathol
. 2017 Jun;
45(4):444-471.
PMID: 28641506
Available imaging systems for use in preclinical toxicology studies increasingly show utility as important tools in the toxicologic pathologist's armamentarium, permit longitudinal evaluation of functional and morphological changes in tissues,...
16.
Sorensen L, Bedja D, Sysa-Shah P, Liu H, Maxwell A, Yi X, et al.
Comp Med
. 2016 Aug;
66(4):268-77.
PMID: 27538857
Although rare, hypertrophic cardiomyopathy (HCM) with midventricular obstruction is often associated with severe symptoms and complications. None of the existing HCM animal models display this particular phenotype. Our group developed...
17.
Minn I, Koo S, Lee H, Brummet M, Rowe S, Gorin M, et al.
Oncotarget
. 2016 Jul;
7(35):56471-56479.
PMID: 27437764
Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of cases of clear cell renal cell carcinoma (ccRCC), the most common renal cancer. We...
18.
Hsiao P, Kalin J, Sun I, Amin M, Lo Y, Chiang M, et al.
Chembiochem
. 2016 Jul;
17(20):1951-1960.
PMID: 27432157
The adenosine A receptor (A R) is expressed in immune cells, as well as brain and heart tissue, and has been intensively studied as a therapeutic target for multiple disease...
19.
Chatterjee S, Lesniak W, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al.
Oncotarget
. 2016 Feb;
7(9):10215-27.
PMID: 26848870
Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and improved survival in several cancers. PD-L1 expression in tumors may be predictive of response to checkpoint blockade therapy. Because...
20.
Sysa-Shah P, Tocchetti C, Gupta M, Rainer P, Shen X, Kang B, et al.
Cardiovasc Res
. 2015 Dec;
109(3):358-73.
PMID: 26692570
Aims: Despite the observation that ErbB2 regulates sensitivity of the heart to doxorubicin or ErbB2-targeted cancer therapies, mechanisms that regulate ErbB2 expression and activity have not been studied. Since isoproterenol...